Pfizer: Colitis, Ulcerative trials

The registry lists 42 Colitis, Ulcerative studies with Pfizer as lead sponsor. 4 are open to participants now and 26 have results posted.

Phase 1 3Phase 2 12Phase 3 9Phase 4 1No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisRecruitingNCT07470879Phase 2
• An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisRecruitingNCT06398626
• Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.AvailableNCT06025227
• A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisRecruitingNCT05287126Phase 2
• A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or PsoriasisCompletedNCT05796245Results posted
• This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.CompletedNCT05082428Results posted
• Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.TerminatedNCT05069259Results posted
• Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative ColitisCompletedNCT05061446Phase 2Results posted
• Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)CompletedNCT04706793Phase 3Results posted
• Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative ColitisCompletedNCT04607837Phase 2Results posted
• Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis PatientsCompletedNCT04071405Results posted
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisCompletedNCT03996369Phase 3Results posted
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisCompletedNCT03945188Phase 3Results posted
• Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)CompletedNCT03884439Results posted
• Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel DiseaseCompletedNCT03801928Results posted
• Xeljanz Special Investigation for Long-term Use in UC PatientsCompletedNCT03643211Results posted
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable RemissionTerminatedNCT03281304Phase 4Results posted
• Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.TerminatedNCT03269695Phase 2Results posted
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02958865Phase 2Results posted
• National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real LifeCompletedNCT02925338Results posted
• Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel DiseaseCompletedNCT02539368Results posted
• Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT02536404Phase 2Results posted
• Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative ColitisCompletedNCT02447302Phase 2Results posted
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative ColitisCompletedNCT01470612Phase 3Results posted
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01465763Phase 3Results posted
• A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01458951Phase 3Results posted
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisCompletedNCT01458574Phase 3Results posted
• Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis PatientsCompletedNCT01284062Phase 2Results posted
• A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01240915Phase 2Results posted
• A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.CompletedNCT00787202Phase 2Results posted
• An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative ColitisActive, not recruitingNCT07459686
• Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis PopulationCompletedNCT07177209
• A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative ColitisActive, not recruitingNCT06294925
• A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative ColitisTerminatedNCT05549323Phase 1
• Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative ColitisActive, not recruitingNCT04624230Phase 3
• Tofacitinib in Adult Patients With Moderate to Severe Ulcerative ColitisCompletedNCT04424303
• Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In SwedenCompletedNCT04338204
• A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative ColitisWithdrawnNCT04209556Phase 2
• Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In PortugalWithdrawnNCT04156672
• An Extension Study for Treatment of Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT03950232Phase 3
• A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative ColitisCompletedNCT00928681Phase 1
• Study Evaluating rhIL-11 in Left-Sided Ulcerative ColitisTerminatedNCT00038922Phase 1